Fake outbreak news, treating coronavirus, and biotech’s Mount Rushmore

Is peer review underrated? Can biotech stop an outbreak? And would you mind giving us a call?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Sharon Begley joins us to explain how early access to scientific papers has

been crucial — and occasionally problematic — during the novel coronavirus outbreak. Then, we discuss the drug industry’s attempts to find a treatment for the virus. Later, our colleague

Matthew Herper joins us for a thought experiment: If biotech had a Mount Rushmore, who would be on it?

Also: We’re coming up on the 100th episode of this podcast, and we’re using the occasion to actualize our long-held dream of running a call-in show. Dial us at 617-517-6130 and leave a

message with any question you’d like us to answer on the podcast, and you may just hear it on air in the coming weeks.

For more on what we cover, here’s the latest on the coronavirus; here’s what Regeneron Pharmaceuticals is up to; here’s the Mount Rushmore debate; and here’s an update from the State of the

Union address.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].